The Benefit of Brentuximab Vedotin and Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Single-Center Retrospective Study
Aim: To assess the real-world efficacy of brentuximab vedotin and PD-1 inhibitors versus historical chemotherapy-only salvage regimens in relapsed/refractory classic Hodgkin lymphoma. Methods: Retrospective, single-center study of two cohorts (n=30 each) treated between 1996–2012 (historical) and 2...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Romanian Society of Hematology
2025-06-01
|
| Series: | Documenta Haematologica |
| Subjects: | |
| Online Access: | https://www.dhrrh.ro/wp-content/uploads/2025/06/DHRRH-2025-2-art2.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Aim: To assess the real-world efficacy of brentuximab vedotin and PD-1 inhibitors versus historical chemotherapy-only salvage regimens in relapsed/refractory classic Hodgkin lymphoma.
Methods: Retrospective, single-center study of two cohorts (n=30 each) treated between 1996–2012 (historical) and 2017–2021 (immunotherapy), with survival endpoints (OS, PFS, EFS1-3) analyzed by Kaplan–Meier and log-rank tests.
Results: The immunotherapy group achieved a higher overall response rate (80% vs. 36.7%, p=0.001), longer median OS (47 vs. 30 months) and superior EFS1–3 (33 vs. 16 months, 32.5 vs. 8 months, 38 vs. 23 months; all p<0.05) compared to historical controls.
Conclusion: Incorporation of brentuximab vedotin and PD-1 blockade before and after autologous SCT significantly improves response and survival outcomes in relapsed/refractory Hodgkin lymphoma, supporting earlier use of these agents in salvage and frontline settings. |
|---|---|
| ISSN: | 3008-220X 2972-242X |